Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Effectiveness, Safety and Patient-reported Outcomes of Setmelanotide in Patients With Bardet-Biedl Syndrome: A Prospective Mono Centric Observational Interventional Study

NCT07674290 is registered in ClinicalTrials.gov with Tom Hühne as lead sponsor.

NCT NCT07674290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Effectiveness, Safety and Patient-reported Outcomes of Setmelanotide in Patients With Bardet-Biedl Syndrome: A Prospective Mono Centric Observational Interventional Study
Lead sponsor
Tom Hühne
Phase
Phase 4
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 31, 2030
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alstrom syndrome, bardet biedl syndrome, bardet biedl syndrome (bbs), bardet-biedl syndrome (bbs)